orming expectations in 17 International markets; Sculptra®gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfolio of flagship brands.

Significant progress and strategic investments across a robust innovation pipeline, highlighted by key submissions and approvals from the broadest pipeline in the industry in Injectable Aesthetics, the introduction of scientifically-differentiated products in Dermatological Skincare, and the initiation of clinical trials for new nemolizumab indications in Therapeutic Dermatology.

Extended scientific leadership in dermatology,with a strong presence at key congresses and industry events as well as market leadership in education.

Core EBITDA grew to 1,211 million USD, up 18.9% year-on-year at constant currency, ahead of net sales growth. Reported Core EBITDA margin was 23.3%, representing a year-on-year margin expansion of 24 basis points a
=*=*=*=*=*=
当前为第2/55页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页